337 related articles for article (PubMed ID: 19077927)
21. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
22. Renal effects of low dose aspirin in elderly patients.
Segal R; Lubart E; Leibovitz A; Iaina A; Caspi D
Isr Med Assoc J; 2006 Oct; 8(10):679-82. PubMed ID: 17125112
[TBL] [Abstract][Full Text] [Related]
23. [Determination of individual kidney function?].
Lipp HP
Med Monatsschr Pharm; 2008 Oct; 31(10):393-5. PubMed ID: 18975414
[No Abstract] [Full Text] [Related]
24. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
[TBL] [Abstract][Full Text] [Related]
25. Short- and long-term follow-up of glomerular and tubular renal markers of kidney function in hyperthyroid cats after treatment with radioiodine.
van Hoek I; Lefebvre HP; Peremans K; Meyer E; Croubels S; Vandermeulen E; Kooistra H; Saunders JH; Binst D; Daminet S
Domest Anim Endocrinol; 2009 Jan; 36(1):45-56. PubMed ID: 19010632
[TBL] [Abstract][Full Text] [Related]
26. Novel algorithm for more accurate calculation of renal function in adults with cancer.
Holweger K; Lipp HP; Dietz K; Hartmann JT; Bokemeyer C
Ann Pharmacother; 2008 Dec; 42(12):1749-57. PubMed ID: 19033483
[TBL] [Abstract][Full Text] [Related]
27. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
28. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
29. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
Herrington JD; Tran HT; Riggs MW
Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
[TBL] [Abstract][Full Text] [Related]
30. [The kidney in children under chemotherapy].
Cachat F; Guignard JP
Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
[TBL] [Abstract][Full Text] [Related]
31. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
32. Azthreonam in the treatment of urinary tract infection: evaluation of efficacy, renal effects and nephrotoxicity.
Donadio C; Tramonti G; Garcea G; Lorusso P; Lucchetti A; Giordani R; Pierotti R; Falcone G; Bianchi C
Drugs Exp Clin Res; 1987; 13(3):167-70. PubMed ID: 3622245
[TBL] [Abstract][Full Text] [Related]
33. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
[TBL] [Abstract][Full Text] [Related]
34. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a formula for individual dosage of nedaplatin based on renal function.
Sato S; Fujiwara H; Oishi T; Shimada M; Machida S; Takei Y; Itamochi H; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Mar; 69(3):599-603. PubMed ID: 21918903
[TBL] [Abstract][Full Text] [Related]
36. Creatinine clearance after cimetidine administration: is it useful in the monitoring of the function of transplanted kidney?
Kabat-Koperska J; Safranow K; Gołembiewska E; Domanski L; Ciechanowski K
Ren Fail; 2007; 29(6):667-72. PubMed ID: 17763160
[TBL] [Abstract][Full Text] [Related]
37. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.
Cavaletti G; Bogliun G; Zincone A; Marzorati L; Melzi P; Frattola L; Marzola M; Bonazzi C; Cantù MG; Chiari S; Galli A; Bregni M; Gianni MA
Anticancer Res; 1998; 18(5B):3797-802. PubMed ID: 9854499
[TBL] [Abstract][Full Text] [Related]
38. Validation of a new plasma cystatin C-based formula and the Modification of Diet in Renal Disease creatinine-based formula for determination of glomerular filtration rate.
Sterner G; Björk J; Carlson J; Grubb A; Nyman U
Scand J Urol Nephrol; 2009; 43(3):242-9. PubMed ID: 19291590
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer.
Hiraike M; Hiraki Y; Misumi N; Hanada K; Tsuji Y; Kamimura H; Karube Y; Kashiwabara K
Cancer Chemother Pharmacol; 2012 Mar; 69(3):845-8. PubMed ID: 22194156
[TBL] [Abstract][Full Text] [Related]
40. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
